Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

[1]  S. Yusuf,et al.  Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.

[2]  William R Shadish,et al.  Propensity Scores , 2005, Evaluation review.

[3]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[4]  E. Antman,et al.  Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. , 2005, Circulation.

[5]  Gregg W Stone,et al.  Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? , 2005, JAMA.

[6]  A. Kastrati,et al.  Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.

[7]  E. Topol,et al.  Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. , 2004, Journal of the American College of Cardiology.

[8]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[9]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. , 2004, The American journal of cardiology.

[10]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[11]  E. Antman,et al.  Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. , 2004, Circulation.

[12]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. , 2004, The American journal of cardiology.

[13]  E. Braunwald.  Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction , 2003, Circulation.

[14]  P. Gurbel,et al.  Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. , 2003, American heart journal.

[15]  Deepak L. Bhatt,et al.  Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). , 2003, Journal of the American College of Cardiology.

[16]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[17]  S. Steinhubl,et al.  Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study: A US Perspective , 2002, Circulation.

[18]  A. Weyrich,et al.  Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. , 2002, Circulation.

[19]  E. Topol,et al.  Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword? , 2002, Circulation.

[20]  S. Sdringola,et al.  Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). , 2001, The American journal of cardiology.

[21]  Deepak L. Bhatt,et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.

[22]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[23]  P. Teirstein,et al.  Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study , 2001, Circulation.

[24]  S. Steinhubl,et al.  Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events: Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial , 2001, Circulation.

[25]  M. Seyfarth,et al.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.

[26]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[27]  V. Fuster,et al.  Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[28]  C. Thalamas,et al.  Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. , 2000, Circulation.

[29]  J. Hauert,et al.  Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. , 1999, Seminars in thrombosis and hemostasis.

[30]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[31]  B. Nowak,et al.  Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. , 1998, Circulation.

[32]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[33]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[34]  F. Neumann,et al.  Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.

[35]  P. Teirstein,et al.  Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[36]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[37]  G. FitzGerald,et al.  Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. , 1989, Circulation.

[38]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.

[39]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[40]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[41]  O S Miettinen,et al.  Stratification by a multivariate confounder score. , 1976, American journal of epidemiology.